Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results From a Phase 3 Trial

Authors

I McInnes
P Mease
C Ritchlin
P Rahman
Alice Gottlieb, New York Medical CollegeFollow
B Kirkham

Document Type

Abstract

Publication Date

April 2017

Journal Title

Rheumatology

Department

Dermatology

Recommended Citation

McInnes, I., Mease, P., Ritchlin, C., Rahman, P., Gottlieb, A., & Kirkham, B. (2017). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results From a Phase 3 Trial. Rheumatology, 56 (Suppl 2), 76. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/95